Shigeki Watanabe

Dr. Shigeki Watanabe

Department of Radiation-Applied Biology, Takasaki Advanced Radiation Research Institute, National Institutes for Quantum and Radiological Science and Technology (QST), Watanuki-machi, Takasaki, Gunma 370-1292, Japan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HSHiroyuki Suzuki
Hiroyuki Suzuki
YKYuta Kaizuka
Yuta Kaizuka
MTMaho Tatsuta
Maho Tatsuta
HTHiroshi Tanaka
Hiroshi Tanaka
NWNana Washiya
Nana Washiya
YAYasushi Arano
Yasushi Arano

4 December 2018 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
Shigeki WatanabeShigeki Watanabe
Shigeki Watanabe
MAMohammad Anwar-Ul Azim
Mohammad Anwar-Ul Azim
INIchiro Nishinaka
Ichiro Nishinaka
ISIchiro Sasaki
Ichiro Sasaki
YOYasuhiro Ohshima
Yasuhiro Ohshima
NINoriko S. Ishioka
Noriko S. Ishioka
Electrophilic desilylation allows for convenient and reproducible synthesis of the aromatic amino acid derivative 4-[211At]astato-l-phenylalanine.

1 September 2018 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
YNYuto Nagao
Yuto Nagao
MYMitsutaka Yamaguchi
Mitsutaka Yamaguchi
Shigeki WatanabeShigeki Watanabe
Shigeki Watanabe
NINoriko S. Ishioka
Noriko S. Ishioka
NKNaoki Kawachi
Naoki Kawachi
Hiroshi WatabeHiroshi Watabe
Hiroshi Watabe

17 August 2021 in Molecules
Verified
Journal Article
Open access
PDF file
RIRyota Imura
Ryota Imura
HIHiroyuki Ida
Hiroyuki Ida
ISIchiro Sasaki
Ichiro Sasaki
NINoriko S. Ishioka
Noriko S. Ishioka
Shigeki WatanabeShigeki Watanabe
Shigeki Watanabe
(1) Background: Deferoxamine B (DFO) is the most widely used chelator for labeling of zirconium-89 (89Zr) to monoclonal antibody (mAb). Despite the remarkable developments of the clinical 89Zr-immuno-PET, chemical species and stability constants of the Zr-DFO complexes remain controversial. The aim of this study was to re-evaluate their stability constants by identifying species of Zr-DFO complexes and demonstrate that the stability constants can estimate radiochemical yield (RCY) and chelator-to-antibody ratio (CAR). (2) Methods: Zr-DFO species were determined by UV and ESI-MS spectroscopy. Stability constants and speciation of the Zr-DFO complex were redetermined by potentiometric titration. Complexation inhibition of Zr-DFO by residual impurities was investigated by competition titration. (3) Results: Unknown species, ZrHqDFO2, were successfully detected by nano-ESI-Q-MS analysis. We revealed that a dominant specie under radiolabeling condition (pH 7) was ZrHDFO, and its stability constant (logβ111) was 49.1 ± 0.3. Competition titration revealed that residual oxalate inhibits Zr-DFO complex formation. RCYs in different oxalate concentration (0.1 and 0.04 mol/L) were estimated to be 86% and >99%, which was in good agreement with reported results (87%, 97%). (4) Conclusion: This study succeeded in obtaining accurate stability constants of Zr-DFO complexes and estimating RCY and CAR from accurate stability constants established in this study.

2 July 2022 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YKYuto Kondo
Yuto Kondo
HKHiroyuki Kimura
Hiroyuki Kimura
ISIchiro Sasaki
Ichiro Sasaki
Shigeki WatanabeShigeki Watanabe
Shigeki Watanabe
YOYasuhiro Ohshima
Yasuhiro Ohshima
NINoriko S. Ishioka
Noriko S. Ishioka

20 January 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
HSHiroyuki Suzuki
Hiroyuki Suzuki
SYSaki Yamashita
Saki Yamashita
STShoko Tanaka
Shoko Tanaka
KKKento Kannaka
Kento Kannaka
ISIchiro Sasaki
Ichiro Sasaki
TUTomoya Uehara
Tomoya Uehara
Purpose: Patients who develop metastatic melanoma have a very poor prognosis, and new treatments are needed to improve the response rates. Melanocortin-1 receptor (MC1R) is a promising target for radionuclide therapy of metastatic melanoma, and alpha-melanocyte stimulating hormone (α-MSH) peptide analogs show high affinities to MC1Rs. Because targeted alpha therapy (TAT) can be a desirable treatment for metastatic melanoma, this study aimed to develop an 211At-labeled α-MSH peptide analog for TAT of metastatic melanoma. Methods: We designed an α-MSH analog labeled with 211At using a neopentyl glycol scaffold via a hydrophilic linker. Preliminary studies using 125I-labeled α-MSH analogs were performed to identify suitable hydrophilic linkers. Then, [211At]NpG-GGN4c was prepared using a procedure similar to that of the 125I-labeled counterpart, [125I]NpG-GGN4b. The biodistribution profile of [211At]NpG-GGN4c in B16F10 tumor-bearing mice was compared with that of [125I]NpG-GGN4b. B16F10 tumor-bearing mice were treated with a single dose of vehicle or [211At]NpG-GGN4c (1 or 0.4 MBq). Results: The D-Glu-D-Arg linker was identified as the optimal hydrophilic linker because of its high affinity for MC1R and good biodistribution profile, especially with low accumulation in the liver and intestine. [211At]NpG-GGN4c showed tumor accumulation comparable to that of [125I]NpG-GGN4b and maintained the tumor radioactivity retention from 1 to 3 h postinjection. [211At]NpG-GGN4c exhibited a dose-dependent inhibitory effect on B16F10 xenograft growth without apparent body weight loss. Conclusion: [211At]NpG-GGN4c showed dose-dependent efficacy against B16F10 xenografts, suggesting that [211At]NpG-GGN4c is a promising TAT agent for treating metastatic melanoma.